Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy

H Azuma; M Oshima; K Ito; A Okuno; I Kawabata; K Banba; H Murahashi; T Sekine; Y Kato; K Ikebuchi; H Ikeda

doi:10.1007/pl00008395

Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy

Eur J Pediatr. 2000 Aug;159(8):633-4. doi: 10.1007/pl00008395.

Authors

H Azuma, M Oshima, K Ito, A Okuno, I Kawabata, K Banba, H Murahashi, T Sekine, Y Kato, K Ikebuchi, H Ikeda

PMID: 10968249
DOI: 10.1007/pl00008395

Abstract

Interleukin-2 production may be one of the underlying causes of Wiskott-Aldrich syndrome immunodeficiency and recombinant interleukin-2 administration (or an infusion of T-cells expanded by CD3 stimulation and rIL-2) is able, to some extent, to restore defective T-cell function.

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal / immunology
Antibodies, Monoclonal / therapeutic use
CD3 Complex / immunology
Humans
Interleukin-2 / immunology*
Interleukin-2 / therapeutic use*
Recombinant Proteins / therapeutic use*
Wiskott-Aldrich Syndrome / blood
Wiskott-Aldrich Syndrome / immunology*
Wiskott-Aldrich Syndrome / therapy*

Substances

Antibodies, Monoclonal
CD3 Complex
Interleukin-2
Recombinant Proteins